TLR regulate myelopoiesis and innate immune responses, but chronic stimulation of TLR can lead to HSPC dysfunction^[@R1]^. Most work has described TLR pathways in immune effector cells, and more recently, in coordinating RNA processing during hematopoietic differentiation^[@R2],[@R3]^. TLRs and their coreceptors are expressed on hematopoietic stem cell (HSC) and important for HSPC function^[@R4]^. Chronic TLR stimulation, such as by lipopolysaccharide (LPS) or during sepsis, induces durable changes in bone marrow (BM) physiology, including reduced HSC self-renewal, myeloid-biased differentiation, and neutropenia^[@R1]^. Thus it is not surprising that chronic TLR signaling is implicated in mediating HSC defects and contributing to MDS^[@R5]--[@R7]^. MDS are clonal HSC disorders defined by cytopenia, myeloid cell dysplasia, and ineffective hematopoiesis^[@R8],[@R9]^. Multiple genetic mechanisms contribute to TLR pathway activation in MDS^[@R5],[@R6],[@R10]--[@R13]^, which converge on the central mediator of innate immune and TNF superfamily receptor signaling, TRAF6. For example, deletion of miR-146a and/or TIFAB, two suppressors of TRAF6 associated with del(5q) MDS result in TRAF6 overexpression^[@R5],[@R14]^. TRAF6 is an E3 ligase that synthesizes lysine (K) 63-linked Ub chains on substrates leading to downstream pathway activation. Despite the association between chronic TLR signaling, diminished HSC fitness, and MDS pathogenesis, the underlying cellular and molecular mechanisms remain unknown. Here we used a hematopoietic-specific TRAF6 overexpression mouse model to describe a mechanism of RNA processing involving ubiquitination of hnRNPA1, an RNA binding protein, by TRAF6, which under conditions of chronic TRAF6 signaling alters RNA splicing and cell-intrinsic HSC defects associated with MDS.

Results {#S1}
=======

Overexpression of TRAF6 impairs HSC function {#S2}
--------------------------------------------

TRAF6 is overexpressed in \~40% of normal karyotype or del(5q) CD34^+^ cells from MDS patients as compared to CD34^+^ cells from healthy individuals ([Fig. 1a](#F1){ref-type="fig"}). To model TRAF6 overexpression and genetically-driven chronic TLR activation observed in MDS HSPC, we generated transgenic mice that overexpress TRAF6 under the control of hematopoietic-specific *Vav* regulatory elements (called *Vav*-TRAF6 mice hereafter)^[@R15],[@R16]^ ([Supplementary Fig. 1a--c](#SD1){ref-type="supplementary-material"}). To avoid supraphysiological expression of TRAF6, we selected transgenic mice in which TRAF6 expression was 2-fold higher as compared to endogenous TRAF6 in wild-type HSPC (LSK, Lineage^−^Sca1^+^cKit^+^), and consistent with TRAF6 overexpression in MDS CD34^+^ cells ([Fig. 1a](#F1){ref-type="fig"}). Beginning at \~5 months, *Vav*-TRAF6 mice succumbed to a BM failure-like disease, with 50% lethality beyond 15 months ([Fig. 1b](#F1){ref-type="fig"}). Moribund *Vav*-TRAF6 mice developed leukopenia and anemia, neutrophil dysplasia and reduced BM cellularity ([Fig. 1c--f](#F1){ref-type="fig"}), and exhibited enlarged spleens due to extramedulary erythro- and myelopoiesis ([Supplementary Fig. 1d--e](#SD1){ref-type="supplementary-material"}). Despite the BM failure, the number of CD34^−^CD135^−^LSK (LT-HSC), CD34^+^CD135^−^LSK (ST-HSC) and CD34^+^CD135^+^LSK (MPP) were elevated in the BM of *Vav*-TRAF6 mice compared to wild-type mice ([Fig. 1g](#F1){ref-type="fig"}). In methylcellulose assays, *Vav*-TRAF6 LSK formed fewer colonies compared to wild-type LSK ([Fig. 1h](#F1){ref-type="fig"}). To assess the consequences of TRAF6 overexpression on HSC function *in vivo*, we competitively transplanted BM mononuclear cells or LT-HSC (CD34^−^CD135^−^LSK) from *Vav*-TRAF6 or wild-type donor mice with equal numbers of wild-type BM cells into lethally-irradiated congenic wild-type recipients. The hematopoietic contribution of *Vav*-TRAF6 BM mononuclear cells to peripheral blood chimerism in primary recipients was moderately reduced compared to wild-type donor BM mononuclear cells or LT-HSC HSC ([Supplementary Fig. 2a,b](#SD1){ref-type="supplementary-material"}). Similarly, hematopoietic contribution of *Vav*-TRAF6 LT-HSC to peripheral blood chimerism following serial transplantation of BM cells in secondary wild-type recipients was reduced compared to wild-type donor LT-HSC ([Supplementary Fig. 2a,b](#SD1){ref-type="supplementary-material"}). Reduced peripheral blood chimerism of *Vav*-TRAF6 BM mononuclear cells- or LT-HSC-derived progeny in recipient mice was mainly due to diminished numbers of CD3^+^ and B220^+^ lymphoid cells as compared to lymphoid cells in recipient mice reconstituted with wild-type BM mononuclear cells or LT-HSC ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). However, BM chimersim of CD34^−^CD135^−^LSK (LT-HSC), CD34^+^CD135^−^LSK (ST-HSC) and CD34^+^CD135^+^LSK (MPP) was similar between *Vav*-TRAF6 and wild-type donor BM mononuclear cells or LT-HSC ([Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"}). We next examined mature immune cells in recipient mice competitively transplanted with BM mononuclear cells or LT-HSC (CD34^−^CD135^−^LSK) from *Vav*-TRAF6 or wild-type donor mice and equal number of wild-type BM cells. Peripheral blood CD11b^+^ myeloid populations were expanded at the expense of CD3^+^ and B220^+^ lymphoid populations within CD45.2^+^ donor-derived *Vav*-TRAF6 BM mononuclear cells (from 27% to 41%) or LT-HSC (from 18% to 40%) when compared to either wild-type donor-derived BM mononuclear cells or LT-HSC cells, or to CD45.1^+^ competitor-derived BM mononuclear cells from wild-type mice after 12 weeks ([Fig. 1i](#F1){ref-type="fig"}, [Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). These observations suggest that TRAF6 overexpression results in HSPC defects that are cell-intrinsic and associated with myeloid-biased differentiation.

To assess if the Ub ligase activity of TRAF6 is required for the observed hematopoietic phenotype, we retrovirally expressed wild-type (TRAF6-LSK) and E3 ligase-defective TRAF6 (TRAF6-C70A-LSK) in BM LSK, which express low levels of endogenous *Traf6*, and examined hematopoietic progenitor colony formation in methylcellulose. TRAF6-LSK formed fewer total colonies upon serial replating as compared to vector-transduced LSK ([Fig. 1j](#F1){ref-type="fig"}). In contrast, TRAF6-C70A-LSK cells formed similar number of colonies as vector-transduced LSK cells ([Fig. 1j](#F1){ref-type="fig"}). We next examined the differentiation potential of TRAF6-LSK and TRAF6-C70A-LSK following competitive transplantation with an equal number of wild-type unfractionated BM cells into lethally-irradiated congenic recipients. Peripheral blood CD11b^+^ myeloid populations were significantly expanded at the expense of CD3^+^ and B220^+^ lymphoid populations within GFP^+^ donor-derived TRAF6-LSK cells compared to donor-derived TRAF6-C70A-LSK or vector-transduced LSK cells after 8 weeks ([Fig. 1k](#F1){ref-type="fig"}). Thus, HSPC expressing the TRAF6 transgene were functionally impaired and showed a myeloid bias *in vivo* that was dependent on the Ub ligase activity of TRAF6.

RNA binding proteins are TRAF6 substrates {#S3}
-----------------------------------------

To determine the molecular pathways regulated by chronic TRAF6 overexpression, we performed microarray gene expression analysis in LSK sorted from the BM of 6 month-old *Vav*-TRAF6 and wild-type mice. 190 genes were differentially expressed in *Vav*-TRAF6 LSK compared to wild-type LSK ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}, [Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Gene set enrichment analysis revealed that *Vav*-TRAF6 LSK have downregulated genes characteristically expressed by quiescent LT-HSC^[@R17]^, such as *Msi2*, *Esr1*, and *Bcl2l11*, and upregulated expression profiles associated with mature hematopoietic cells and myeloid differentiation ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}), including genes encoding *Myc, Mpo*, *E2f8* and *Ccr2* ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). Although NF-κB and immune signaling is associated with normal TRAF6 function, gene expression profiles related to immune and inflammatory responses were not upregulated in *Vav*-TRAF6 LSK compared to wild-type LSK ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). The amount of phosphorylated IKKβ was similar in *Vav*-TRAF6 and wild-type Lin- BM cells (**not shown**), cytokines, such as *Il1a, Il2, Il3, Ifng*, and *Il6* were comparable in the peripheral blood of *Vav*-TRAF6 and wild-type mice (**not shown**), and inflammation or immune cell infiltration was not detected in moribund *Vav*-TRAF6 mice (**not shown**), indicating that the hematopoietic phenotype in *Vav*-TRAF6 mice was not associated with activation of canonical NF-κB signaling and/or inflammation. As such, we broadened our mechanistic investigation by searching for ubiquitinated substrates of TRAF6. For this, we performed global semi-quantitative Ub capture proteomics in a TRAF6-overexpressing human leukemia cell line (TF1) engineered to express a doxycycline-inducible shRNA targeting TRAF6 ([Fig. 2a](#F2){ref-type="fig"}). Ubiquitinated peptides immunoprecipitated from doxycycline-treated TF1 cells to induce TRAF6 knockdown or from vehicle-treated TF1 cells as controls were analyzed by mass spectrometry ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). The proteomic analysis identified 40 unique peptides from 29 proteins that were ubiquitinated in vehicle-treated TF1 cells, but not in doxycycline-treated TRAF6-knockdown TF1 cells ([Fig 2a](#F2){ref-type="fig"}, [Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}, [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). We performed ubiquitiation assays with recombinant ubiquitin activating enzyme E1 (UBE1), E2 ubiquitin conjugating enzyme Ubc13 (UBE2N/UBE2V1), TRAF6 and Ub with the 29 putative protein substrates. Eleven of the 29 candidate proteins, hnRNPA1, MATR3, RPL3, RPS2, RPS20, RPS27A, HIST2H2BE, YWHAQ, MPP1, GART, and PFN1 were ubiquitinated by TRAF6 in at least one replicate assay ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Gene ontology analysis indicated that 6 of the 11 TRAF6 substrates, hnRNPA1, MATR3, RPL3, RPS2, RPS20 and RPS27A represented RNA-binding proteins ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Table 2](#SD2){ref-type="supplementary-material"}). Thus, we conclude that TRAF6 overexpression resulted in transcriptional changes and ubiquitination of RNA-binding proteins in HSPC.

TRAF6 regulates RNA splicing via hnRNPA1 {#S4}
----------------------------------------

RNA-binding proteins have pleotropic effects on RNA stability, splicing and translation. To explore whether ubiquitination of RNA-binding proteins by TRAF6 results in altered RNA splicing, we performed a microarray exon expression analysis in LSK cells sorted from *Vav*-TRAF6 and wild-type mice. Two splicing metrics (Splicing Index and FIRMA), which calculate the relative expression of individual exons normalized to all exons within the corresponding gene^[@R18],[@R19]^, were implemented. Three hundred sixteen genes exhibited changes in exon usage in *Vav*-TRAF6 LSK as compared to wild-type LSK (n = 521 exons using the Splicing Index; n = 1919 exons using the FIRM Index) ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). A subset of exons with altered usage in *Vav*-TRAF6 LSK was validated by RT-PCR. Among the 10 exons selected, 6 were alternatively spliced in independent cohorts of *Vav*-TRAF6 LSK as compared to wild-type LSK: *Mllt1* exon 2, *Cep164* exon 7, *Mtmr1*4 exon 18, *Slmap* exon 10, *Sema4g* exon 13 and *Arhgap1* exon 2 ([Supplementary Fig. 5](#SD1){ref-type="supplementary-material"}). To identify the mechanistic link between the ubiquitinated RNA-binding proteins and altered RNA exon usage in *Vav*-TRAF6 HSPC, we performed RNA-binding motif- and RNA-splicing pattern-enrichment analyses of alternatively-spliced cassette exons in sorted *Vav*-TRAF6 LSK. For the motif-enrichment analysis, we examined RNA-binding models in the form of position frequency matrix motifs in the CisBP-RNA database to identify over-representation of RNA-protein binding sites within alternatively-spliced cassette exons in *Vav*-TRAF6 LSK^[@R20]^. Significant enrichment of binding motifs for ELAV1/2/3/4, SRSF7, hnRNPA1, ZFP36 and snRNPA/B2 were found in the alternatively spliced exon sequences in *Vav*-TRAF6 LSK as compared to wild-type LSK ([Fig. 2c](#F2){ref-type="fig"}, [Supplementary Table 4](#SD2){ref-type="supplementary-material"}). These findings were independently confirmed using a hypergeometric test, which measures consensus-based binding site enrichment (**not shown**). We next performed an RNA splicing signature analysis to compare exon-usage patterns of *Vav*-TRAF6 LSK with the RNA exon splicing patterns associated with RNA-binding proteins from published data sets. Exon-usage patterns associated with 11 RNA-binding proteins, namely RBM4, Fus2, Mbnl2, PTB, Nova1/2, Ddx5, hnRNPA1, Musashi2, Rbfox1, PRMT6 and Mbnl1 were significantly enriched in *Vav*-TRAF6 LSK compared to wild-type LSK ([Fig. 2d](#F2){ref-type="fig"}). hnRNPA1 emerged as the only RNA-binding protein that was ubiquitinated by TRAF6 whose binding motifs and global RNA splicing pattern were significantly enriched in LSK from *Vav*-TRAF6 mice. Thus, TRAF6 overexpression in HSPC results in RNA splicing changes associated with hnRNPA1.

TRAF6 directly ubiquitinates hnRNPA1 {#S5}
------------------------------------

Because hnRNPA1 has been implicated in human myeloid malignancies^[@R21]^, we selected it for further validation. Recombinant protein ubiquitination assays showed that hnRNPA1 was ubiquitinated by TRAF6 to a similar magnitude as TAK1, a known TRAF6 substrate^[@R22]^ ([Fig. 3a](#F3){ref-type="fig"}), indicating that hnRNPA1 is a direct substrate of TRAF6. Doxycycline-treated TRAF6-knockdown TF1 cells showed reduced hnRNPA1 ubiquitination compared to vehicle-treated TF1 cells ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). Conversely, transfection of TRAF6 in HEK293 cells resulted in increased hnRNPA1 ubiquitination in the presence of wild-type Ub or Ub that only forms K63-linkages (Ub^K63^) compared to HEK293 cells transfected with empty vector ([Fig. 3b](#F3){ref-type="fig"}, [Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}). In contrast, expression of TRAF6 together with Ub that only forms K48-linkages (Ub^K48^) did not result in hnRNPA1 ubiquitination in HEK293 cells ([Fig. 3b](#F3){ref-type="fig"}). Compared to wild-type TRAF6, transfection of TRAF6-C70A in HEK293 cells did not result in ubiquitination of hnRNPA1 ([Fig. 3c](#F3){ref-type="fig"}), indicating that the E3 ligase domain of TRAF6 was required for hnRNPA1 ubiquitination.

The proteomic analyses indicated that hnRNPA1 was ubiquitinated on Lys3 (K3) ([Fig. 3d](#F3){ref-type="fig"}), which is adjacent to the first RNA-recognition motif (RRM1) of hnRNPA1^[@R23]^. To determine whether hnRNPA1 RRM1 is ubiquitinated by TRAF6, we transfected TRAF6 with a mutant hnRNPA1 protein, in which Lys3 was substituted for arginine (hnRNPA1^K3R^) in HEK293 cells. Compared to wild-type hnRNPA1, ubiquitination of hnRNPA1^K3R^ by TRAF6 was modestly reduced ([Fig. 3d](#F3){ref-type="fig"}), suggesting additional Lys residues in hnRNPA1 can be ubiquitinated by TRAF6. Because ubiquitination of a substrate motif can be promiscuous, resulting in modification of adjacent Lys residues, we additionally mutated the 5 Lys residues within RRM1 adjacent to Lys3 (hnRNPA1^K-R^ hereafter). Transfection of TRAF6 with hnRNPA1^K-R^ in HEK293 cells resulted in further reduction in hnRNPA1 ubiquitination as compared to ubiquitination of wild-type hnRNPA1 or hnRNPA1^K3R^ by TRAF6 ([Fig. 3d](#F3){ref-type="fig"}), indicating that hnRNPA1 ubiquitination by TRAF6 primarily occurs at RRM1. We next examined the ubiquitination of hnRNPA1 by TRAF6 in primary hematopoietic stem and progenitor Lin^−^ BM cells. Immunoprecipitation of endogenous hnRNPA1 indicated that ubiquitination of hnRNPA1 was increased in *Vav*-TRAF6 Lin^−^ BM cells or in LPS-stimulated Lin^−^ BM cells compared to wild-type Lin^−^ BM cells ([Fig. 4a](#F4){ref-type="fig"}). We next used shRNAs to knock down hnRNPA1 in wild-type and *Vav*-TRAF6 Lin^−^ BM cells ([Fig. 4b](#F4){ref-type="fig"}). Knockdown of hnRNPA1 in *Vav*-TRAF6 Lin^−^ BM cells (shA1-*Vav*-TRAF6) resulted in modestly increased total colony formation after serial replating compared to *Vav*-TRAF6 Lin^−^ BM cells expressing a non-targeting shRNA (shCtl-*Vav*-TRAF6)([Fig. 4c](#F4){ref-type="fig"}). Next, shA1 or shCtl *Vav*-TRAF6 and wild-type Lin^−^ BM cells were competitively transplanted with wild-type BM mononuclear cells into lethally-irradiated wild-type mice. shA1-*Vav*-TRAF6 Lin^−^ BM showed improved engraftment of peripheral blood CD45.2^+^GFP^+^ cells from 0.3% to 1.6% as compared to shCtl-*Vav*-TRAF6 Lin^−^ BM cells, while shA1-wild-type Lin- BM cells showed reduced engraftment as compared to shCtl-wild-type Lin^−^ BM cells ([Fig. 4d](#F4){ref-type="fig"}). These findings suggest that hnRNPA1 was ubiquitinated by TRAF6 and this interaction played a role in the hematopoietic phenotype of *Vav*-TRAF6 mice.

TRAF6 induces splicing of *Arhgap1* RNA {#S6}
---------------------------------------

hnRNPA1 regulates RNA splicing by directly binding RNA consensus sites^[@R24]--[@R26]^ or indirectly through protein-RNA interactions^[@R27]^. To identify alternatively spliced genes implicated in the hematopoietic phenotype of *Vav*-TRAF6 mice we focused on the most significantly altered exons in *Vav*-TRAF6 LSK, as revealed by the exon expression analysis. The top genes with differential exon usage included *Flna*, *Il18rap*, *Arhgap1*, *Mcm6*, *Itpr1*, *Laptm5*, *Celf1* and *Fbxw2* ([Fig. 5a](#F5){ref-type="fig"}, [Supplementary Table 3](#SD2){ref-type="supplementary-material"}). Arhgap1 (or Cdc42GAP), an inhibitor of Cdc42 by hydrolysing GTP, was previously implicated in LT-HSC self-renewal and differentiation^[@R28]--[@R30]^ and as such emerged as the most relevant candidate. Exon 2 of *Arhgap1* was excluded in *Vav*-TRAF6 LSK, but not wild-type LSK ([Fig. 5b](#F5){ref-type="fig"}). RT-PCR using primers flanking *Arhgap1* exon 2 and Sanger sequencing showed exclusion of exon 2 in *Vav*-TRAF6 Lin^−^ BM cells and in LPS-stimulated wild-type Lin^−^ BM cells ([Fig. 5c,d](#F5){ref-type="fig"}). To establish whether hnRNPA1 is required for TRAF6-induced exclusion of *Arhgap1* exon 2, *Vav*-TRAF6 or wild-type Lin^−^ BM cells were transduced with hnRNPA1-shRNA (shA1) or a non-targeting-shRNA (shCtl). Knockdown of hnRNPA1 in *Vav*-TRAF6 Lin^−^ BM cells significantly reduced *Arhgap1* exon 2 exclusion compared to sh-Ctl-*Vav*-TRAF6 Lin^−^ BM cells ([Fig. 5e](#F5){ref-type="fig"}). We also investigated *Arhgap1* exon 2 exclusion in wild-type and *Traf6*^−/−^ Lin^−^ BM cells following LPS stimulation. LPS treatment resulted in exclusion of *Arhgap1* exon 2 in wild-type Lin^−^ BM cells but not in *Traf6*^−/−^ Lin^−^ BM cells ([Fig. 5f](#F5){ref-type="fig"}), suggesting that *Arghap1* exon 2 exclusion requires TRAF6.

To gain further insight into the regulation of *Arhgap1* exon 2 exclusion we generated an *Arhgap1* exon 2 cassette splicing reporter in HEK293 cells (HEK293-*Arhgap1*exon2)^[@R31]^. *Arhgap1* exon 2 or the flanking introns do not contain a conserved hnRNPA1 RNA binding motif (**not shown**). However, transfection of hnRNPA1 into HEK293-*Arhgap1*exon2 cells resulted in exclusion of *Arhgap1* exon 2 from the splicing reporter compared to vector-transfected HEK293-*Arhgap1*exon2 cells ([Fig. 5g](#F5){ref-type="fig"}). In addition, transfection of TRAF6, but not of the E3 ligase-defective TRAF6-C70A, into HEK293-*Arhgap1*exon2 cells lead to exclusion of *Arhgap1* exon 2 from the splicing reporter ([Fig. 5h](#F5){ref-type="fig"}). To investigate whether TRAF6-mediated exon skipping is through an hnRNPA1 ubiquitination-dependent mechanism, we co-expressed TRAF6 and hnRNPA1, hnRNPA1^K3R^ or hnRNPA1^K-R^ in HEK293-*Arhgap1*exon2 cells. Expression of TRAF6 and hnRNPA1 resulted in increased exclusion of *Arhgap1* exon 2 from the splicing reporter as compared to TRAF6 alone ([Fig. 5i](#F5){ref-type="fig"}), while expression of hnRNPA1^K-R^, and to a lesser extent hnRNPA1^K3R^, were not as effective as hnRNPA1 to induce *Arhgap1* exon 2 exclusion ([Fig. 5i](#F5){ref-type="fig"}). To evaluate whether ubiquitination of hnRNPA1 affected it's binding to *Arhgap1* exon 2, we performed RNA-immunopreciptation for Arhgap1 *exon 2* in HEK293-*Arhgap1*exon2 cells transfected with TRAF6 and hnRNPA1 or hnRNPA1^K-R^. Transfection of TRAF6 and hnRNPA1 resulted in increased binding of hnRNPA1 to *Arhgap1* cassette exon 2 by 4-fold compared to transfection of only hnRNPA1 ([Fig. 5j](#F5){ref-type="fig"}). In contrast, transfection of TRAF6 and hnRNPA1^K-R^ resulted in increased binding of hnRNPA1^K-R^ to *Arhgap1* cassette exon 2 by only 2-fold as compared to hnRNPA1 alone ([Fig. 5j](#F5){ref-type="fig"}). These data suggest that ubiquitination of Lys residues within the RRM1 of hnRNPA1 by TRAF6 enhanced the binding to *Arhgap*1 cassette exon 2, resulting in exon exclusion.

Exclusion of exon 2 results in reduced Arhgap1 protein {#S7}
------------------------------------------------------

Arhgap1 contains a conventional open-reading frame (ORF) initiated within exon 4 and an upstream ORF (uORF) within exon 1. The uORF is terminated by a stop codon encoded within exon 2 ([Fig. 6a](#F6){ref-type="fig"}). To examine the consequences of exon 2 exclusion on Arhgap1 protein, we transfected hemagglutinin (HA)-tagged Arhgap1 cDNAs with the *Arhgap1* 5' UTR (WT-UTR-Arhgap1) or without the *Arhgap1* 5' UTR (ΔUTR-Arhgap1) in HEK293 cells and evaluated protein expression by immunoblotting with Arhgap1 or HA antibodies. Transfection of ΔUTR-Arhgap1 or WT-UTR-Arhgap1 resulted in translation of Arhgap1 from the conventional ORF (*Arhgap1* ORF) as evident by the 50kD Arhgap1 protein ([Fig. 6a](#F6){ref-type="fig"}). In contrast, deletion of exon 2 within the 5' UTR (ΔExon2-UTR-Arhgap1) resulted in absence of Arhgap1 protein expression from the conventional *Arhgap1* ORF ([Fig. 6a](#F6){ref-type="fig"}). Moreover, transfection of ΔExon2-UTR-Arhgap1 resulted in translation from the uORF and generated a chimeric Arghap1 protein with 40 additional N-terminal amino acids ([Fig. 6a](#F6){ref-type="fig"}). Mutation of the stop codon within exon 2 (TAA:GCC-UTR-Arhgap1) resulted in reduced expression of Arhgap1 protein from the conventional ORF ([Fig. 6a](#F6){ref-type="fig"}) and utilization of the uORF to produce a chimeric Arhgap1 protein with 65 additional N-terminal amino acids ([Fig. 6a](#F6){ref-type="fig"}). These findings revealed that exclusion of *Arhgap1* exon 2 prevented translation of *Arhgap1* from the ORF and induced alternative ORF usage.

The consequences of exon 2 exclusion on Arhgap1 RNA and protein expression were next examined in *Vav*-TRAF6 LSK. As assessed by microarray and qRT-PCR, *Arhgap1* mRNA expression was comparable in wild-type and *Vav*-TRAF6 LSK ([Fig. 6b](#F6){ref-type="fig"}). In wild-type Lin^−^ BM cells, Arhgap1 protein was expressed from the conventional ORF as determined by immunoblotting ([Fig. 6c](#F6){ref-type="fig"}). In contrast, Arhgap1 protein expression from the conventional ORF was reduced in *Vav*-TRAF6 compared to wild-type Lin^−^ BM cells ([Fig. 6c,d](#F6){ref-type="fig"}), suggesting that exon 2 is required for proper Arhgap1 protein expression. The chimeric Arhgap1 protein derived from the uORF was not detectable in primary *Vav*-TRAF6 Lin^−^ BM cells ([Fig. 6c](#F6){ref-type="fig"}) for reasons that remain unclear. However, we observed that Cdc42-GTP was significantly higher in *Vav*-TRAF6 Lin^−^ BM cells compared to wild-type Lin^−^ BM cells ([Fig. 6c,d](#F6){ref-type="fig"}), suggesting increased Cdc42 activation. These findings indicate that TRAF6 overexpression induces exclusion of *Arhgap1* exon 2 leading to diminished Arhgap1 protein and Cdc42 activation in HSPC.

The hematologic phenotype and reduced Arhgap1 protein expression in *Vav*-TRAF6 mice was reminiscent of the phenotype of Arhgap1-deficient mice, which exhibit increased Cdc42 activity, impaired hematopoiesis and myeloid-biased differentiation^[@R28]--[@R30]^. Similar with *Vav*-TRAF6 mice, *Arhgap1*^+/−^ neutrophils exhibit a dysplastic phenotype ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). To investigate whether Cdc42 activation contributes causally to the hematopoietic defects observed in *Vav*-TRAF6 mice, we used the selective inhibitor CASIN to inhibit Cdc42 in HSC^[@R28],[@R32]^. Two hundred LT-HSC (CD34^−^CD135^−^LSK) sorted from CD45.2^+^ *Vav*-TRAF6 mice were either directly transplanted with 2x10^5^ wild-type CD45.1^+^ BM cells into irradiated wild-type congenic mice, or treated with CASIN (or control DMSO) for 24 hr and then transplanted with 2x10^5^ wild-type CD45.1 BM cells into irradiated wild-type mice. *Vav*-TRAF6 LT-HSC (transplanted either directly or after overnight culture in media containing DMSO) had generated \~65% Gr1^+^CD11b^+^ myeloid cells of the CD45.2^+^ donor-derived peripheral blood compared to \~35% wild-type Gr1^+^CD11b^+^ cells 8 weeks post transplantation ([Fig. 7a,b](#F7){ref-type="fig"}). However, CASIN-treated *Vav*-TRAF6 LT-HSC formed fewer Gr1^+^CD11b^+^ myeloid cells among donor (CD45.2^+^)-derived peripheral blood from 37% to 66% compared to DMSO-treated *Vav*-TRAF6 LT-HSC after 8 weeks ([Fig. 7a,b](#F7){ref-type="fig"}). Reduced chimerism from CASIN-treatment of *Vav*-TRAF6 LT-HSC resulted from fewer CD45.2^+^-donor Gr1^+^CD11b^+^ myeloid cells and increased CD3^+^ and B220^+^ lymphoid cells relative to wild-type CD45.1^+^ myeloid and lymphoid cells in peripheral blood ([Fig. 7c](#F7){ref-type="fig"}). In addition, intraperitoneal injection of CASIN or PBS as control for 16 continuous days after adoptive transfer of 200 *Vav*-TRAF6 LT-HSC and 2x10^5^ wild-type BM competitor cells into lethally-irradiated wild-type mice, resulted in expansion of *Vav*-TRAF6 CD45.2^+^CD11b^+^ myeloid cells by \~50% as compared to wild-type CD45.1^+^CD11b^+^ over 4 weeks in PBS-treated chimeric mice, whereas *Vav*-TRAF6 CD45.2^+^CD11b^+^ frequencies did not increase over 4 weeks in CASIN-treated chimeras ([Fig. 7d](#F7){ref-type="fig"}). These findings suggest that Cdc42 activation can cause the myeloid bias observed in the *Vav*-TRAF6 mice.

Cdc42 activation is associated with human MDS {#S8}
---------------------------------------------

Next, we assessed alternative RNA splicing changes of Arhgap family members in publically available data sets from human MDS-AML samples and cell lines^[@R33]--[@R35]^. We identified significant RNA splicing alterations of *ARHGAP11b*, *ARHGAP17*, *ARHGAP19* and *ARHGAP22* in MDS and AML BM CD34^+^ cells and cell lines. *A*mong these, ARHGAP17 undergoes exclusion of exon 18 in a human monocytic leukemic cells (THP1) following LPS stimulation^[@R34]^ and in an MDS patient-derived human cell line (MDSL) ([Fig. 8a](#F8){ref-type="fig"}, [Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}). To establish the contribution of TRAF6 to *ARHGAP17* exon 18 exclusion, MDSL cells were transduced with shRNAs targeting TRAF6 (shTRAF6-MDSL) or a non-targeting shRNA (shCtl-MDSL). RT-PCR using primers flanking exons 17 and 18 or exon 18 of *ARHGAP17* showed that shTRAF6-MDSL have restored expression of the *ARHGAP17* exon 17, 18 and 19 cassette compared to shCtl-MDSL cells ([Fig. 8a,b](#F8){ref-type="fig"}). In human MDS BM cells, exclusion of exon 18 resulted in premature termination of ARHGAP17 protein ([Supplementary Fig. 7a](#SD1){ref-type="supplementary-material"}), while inclusion of *ARHGAP17* exon 18 in shTRAF6-MDSL cells resulted in restored ARHGAP17 protein expression ([Fig. 8b](#F8){ref-type="fig"}), indicating that exon 18 is essential for proper ARHGAP17 protein expression. The splice junctions between exons 16, 17, 18 and 19, and between exons 17 and 19 of *ARHGAP17* in MDSL cells were independently confirmed by Sanger sequencing ([Fig. 8c](#F8){ref-type="fig"}). As we observed in shTRAF6-MDSL cells, shRNA-mediated knockdown of hnRNPA1 in MDSL cells (shA1-MDSL) resulted in restoration of full-length *ARHGAP17* mRNA, and expression of ARHGAP17 protein ([Supplementary Fig. 7b--d](#SD1){ref-type="supplementary-material"}).

We next determined whether *ARHGAP17* exon 18 exclusion is associated with *TRAF6* overexpression in primary human MDS. RT-PCR analysis of BM mononuclear cells showed that increased *TRAF6* expression correlated with exclusion of *ARHGAP17* exon 18 in MDS patients and normal BM cells ([Fig. 8d](#F8){ref-type="fig"}). In addition, we examined *TRAF6* expression and *ARHGAP17* exon 18 exclusion by qRT-PCR in larger cohort of primary MDS and AML BM mononuclear cells. Using primers aligning to the splice junction of exons 17--19 of *ARHGAP17*, we found that increased *TRAF6* mRNA positively correlated with exclusion of exon 18 from *ARHGAP17* in MDS/AML samples ([Fig. 8e](#F8){ref-type="fig"}), indicating that TRAF6 overexpression is associated with alternative RNA splicing of ARHGAP17. Because ARHGAP17 is a negative regulator of Cdc42^[@R36]^, we evaluated the amount of Cdc42-GTP in MDSL cells following TRAF6 knockdown. Cdc42-GTP was significantly lower in shTRAF6-MDSL cells compared to shCtl-MDSL cells ([Fig. 8f](#F8){ref-type="fig"}), indicating that restored ARHGAP17 protein expression suppresses Cdc42 activity. In contrast, knockdown of ARHGAP17 in MDSL cells with a GAP17-shRNA resulted in increased Cdc42-GTP relative to MDSL cells expressing a non-targeting shRNA (shCtl-MDSL) ([Fig. 8g](#F8){ref-type="fig"}). Moreover, transduction of GAP17-shRNA in primary human CD34^+^ cells resulted in reduced total colony formation as compared to non-targeting shRNA (shCtl) CD34^+^ cells ([Fig. 8h](#F8){ref-type="fig"}). As such, lower ARHGAP17 expression, as observed following exclusion of exon 18 in MDS and increased Cdc42 activation impairs human CD34^+^ HSPC function. Taken together, alternative splicing of *Arhgap* proteins contributes to increased Cdc42 activation and aberrant hematopoiesis following activation of TRAF6 in MDS ([Supplementary Fig. 7e](#SD1){ref-type="supplementary-material"}).

Discussion {#S9}
==========

Our results show that TRAF6 affects HSPC function by regulating exon specification through ubiquitination of the RNA binding protein hnRNPA1, and provide insight into how hematopoietic cells regulate RNA isoform expression during TLR signaling. We identified several hnRNP family members as potential TRAF6 substrates. Thus, it is possible that TRAF6 signaling downstream of TLR, IL-1R, and/or TNF superfamily of receptors coordinate RNA processing via ubiquitination of multiple auxiliary RNA splicing factors. Our mechanistic interrogation revealed that in the presence of TRAF6, hnRNPA1 induces exclusion of *Arhgap1* exon 2. The precise mechanism by which ubiquitination of hnRNPA1 controls *Arhgap1* exon 2 splicing or globally regulates RNA processing is not conclusive, as hnRNPs can couple RNA splicing with nuclear export, and/or affect RNA splicing directly by binding RNA response elements or in *trans* through protein interactions with other RNA splicing proteins^[@R37]^. Multiple independent genetic alterations and molecular mechanisms have been reported that suggest chronic immune-related signaling contributes to the pathogenesis of MDS. These MDS-associated alterations converge on activating the TRAF6 signaling complex^[@R38]^. Chronic inflammation mediates pleotropic affects on hematopoiesis by cell autonomous and non-autonomous mechanisms. Moreover, chronic immune signaling has durable and irreversible effects on HSC function^[@R1],[@R39],[@R40]^. Although an inflammatory BM milieu and/or altered immune effector cells may contribute to HSC dysfunction and MDS, our results clearly demonstrate that TRAF6 induces cell-intrinsic HSC defects. TRAF6 mediates RNA splicing of *Arhgap1* and activation of the small GTPase, Cdc42, which confers at least part of the hematopoietic phenotype in *Vav*-TRAF6 mice. Mice with constitutively elevated Cdc42 activity, as a consequence of Arhgap1 deletion, display pre-mature aging phenotypes in multiple tissues, including HSCs^[@R41]^. Innate immune signaling and inflammation are also thought to be implicated in aged HSC^[@R1],[@R42]^, which would provide a mechanistic explanation for Cdc42 activation in aged HSC. In summary, we demonstrate that RNA processing in hematopoietic cells is regulated by TRAF6-mediated ubiquitination of a RNA binding protein, hnRNPA1, and that chronic innate immune signaling via TRAF6 impairs HSPC function and contributes to the pathogenesis of MDS through altered splicing of HSC-requisite genes.

Methods {#S10}
=======

Mice and primary murine bone marrow cell culture {#S11}
------------------------------------------------

Generation of the *Vav*-TRAF6 mice was accomplished by cloning a flag tagged human *TRAF6* cDNA downstream of the *Vav* promoter, followed by pronuclear microinjection of linearized *Vav*-FLAG-TRAF6 fragment into fertilized eggs. Mouse and human TRAF6 protein have 92% amino acid identity and functional conservation. The eggs were then transferred into pseudopregnant FVB/NJ mice. *Vav*-TRAF6 mice were also subsequently backcrossed onto C57Bl/6 genetic background. *TRAF6*^fl/fl^ mice (C57Bl/6) were a kind gift from Dr. Yongwon Choi (University of Pennsylvania)^[@R43]^. *Traf6^fl/fl^* mice were crossed with Mx1-Cre and *Vav*-Cre mice for inducible or conditional deletion of TRAF6 (*Traf6*^fl/fl^;Mx1-Cre) and (*Traf6*^fl/fl^;*Vav*-Cre), respectively. To delete TRAF6, Cre transgene expression in *Traf6*^fl/fl^;Mx1-Cre mice was induced by five polyinosinic-polycytidylic acid (pIpC) injections. BM cells were obtained by crushing the femur, tibia, and pelvic bone, and maintained in RPMI1640 with 10% fetal bovine serum. The media was supplemented with recombinant mouse stem cell factor (rmSCF, 02931, StemCell Technologies), mouse interleukin 3 (rmIL-3, 02903, StemCell Technologies) and human interleukin 6 (rhIL-6, 02606, StemCell Technologies) at 10 ng/mL. All mice were bred, housed and handled in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility of Cincinnati Children's Hospital Medical Center.

BM transplantation {#S12}
------------------

For competitive repopulation, 3 x 10^6^ CD45.2^+^ MNCs from WT (C57Bl/6) and *Vav*-TRAF6 (C57Bl/6) mice (2 donor mice, 3 months old) were mixed with 3x10^6^ CD45.1^+^ B6.SJL^Ptprca\ Pep3b/BoyJ^ MNCs (6--10 weeks of age), and then transplanted into lethally-irradiated recipient mice (CD45.1^+^ B6.SJL^Ptprca\ Pep3b/Boy^; 6--10 weeks of age). Alternatively, 200 LT-HSC (Lin^−^cKit^+^Sca1^+^CD34^−^CD135^−^) from WT (C57Bl/6) and *Vav*-TRAF6 (C57Bl/6) mice (2 donor mice, 6--8 moths old) were mixed with 2 x 10^5^ CD45.1^+^ MNCs (6--10 weeks of age), and then transplanted into lethally-irradiated recipient mice (CD45.1^+^ B6.SJL^Ptprca\ Pep3b/BoyJ^; 6--10 weeks of age). For ex vivo CASIN experiments, 200 LT-HSC (Lin^−^cKit^+^Sca1^+^CD34^−^CD135^−^) from *Vav*-TRAF6 mice (6--8 months old) were treated with 5 µM CASIN for 24 hours, and were then mixed with 2 x 10^5^ CD45.1^+^ B6.SJL^Ptprca\ Pep3b/BoyJ^ MNCs (6--10 weeks of age) prior to transplantation into lethally-irradiated recipient mice (CD45.1^+^ B6.SJL^Ptprca\ Pep3b/BoyJ^; 6--10 weeks of age). For in vivo delivery of CASIN, CASIN (30 mg/kg mixed with Dextran) and control vehicle PBS were intraperitoneally injected in recipient mice for 16 consecutive days.

Retroviral expression of TRAF6 in mouse HSPC BM cells {#S13}
-----------------------------------------------------

For WT and E3 ligase-defective (C70A) TRAF6 overexpression, HSPC-enriched Lin- BM cells were obtained from C57Bl/6 or *Traf6*^fl/fl^;*Vav*-Cre mice, and then infected with retroviral vectors (co-expressing GFP, see plasmid description below). Cells were flow-sorted for GFP^+^ cells after 72 hours and then examined for colony formation in methylcellulose or for PB reconstitution in lethally-irradiated mice (CD45.1^+^ B6.SJL^Ptprca\ Pep3b/BoyJ^; 6--10 weeks of age).

Hematological and histological analysis {#S14}
---------------------------------------

Peripheral blood was collected by cheek piercing or cardiac puncture. Blood counts were measured with a hemacytometer (HEMAVET^®^). Spleens and tibias were fixed with 4% PFA, sectioned and stained with H&E for histopathological analysis. Cytospin was performed with 2 x 10^5^ BM cells. Blood smear and cytospin were stained with Wright-Giemsa for morphological analysis. Dysplastic cells were evaluated on at least 100 cells per mouse and confirmed by a pathologist. For neutrophils with Pelger-Huet anomalies, hyposegmentation as a bilobed nucleus was present.

Exon array analysis {#S15}
-------------------

HSPC-enriched LSK cells were sorted from WT (FVB/NJ) and *Vav*-TRAF6 mice (FVB/NJ) (6 months of age). Total RNA was extracted from LSK cells and purified with Quick-RNA MiniPrep Kit (Zymogen). RNA quality was tested using the Agilent Bioanalyzer 2100 (Hewelett Packard). Total RNA was reverse transcribed and labeled, and hybridized onto GeneChip^®^ Mouse Exon 1.0 ST Array (Affymetrix). Scanning was performed with the Affymetrix GeneChip Scanner 3000 7G and evaluated with the Genechip Operating Software (Affymetrix). Data mining was performed with GeneSpring software (Agilent). Gene set enrichment analysis was performed on a JAVA-based dataset supported by the Broad Institute. ToppGene analysis (<http://toppgene.cchmc.org>) was performed to identify enriched pathways.

Exon usage pattern analysis {#S16}
---------------------------

Detection of alternative splicing events between pairs of biological groups was performed with AltAnalyze (v.2.0.6)^[@R44]^, a python-based program. Briefly, a 'robust multi-chip analysis' (RMA) summarization on the selected CEL files was initially generated, and only the probesets that can be aligned to a single ENSEMBL gene were included. This step generated the gene-level expression statistics and annotations for each ENSEMBL gene and each biological comparison group. The probeset-level expression values were further filtered based on DABG P-values cutoff and absolute expression levels for each biological comparison group. Based on these values, the standard alternative exon statistics (i.e. FIRMA, MiDAS P-value, normalized P-value) were computed for each analyzed probeset relative to the determined gene expression levels. For FIRMA analysis^[@R19]^, Affymetrix probe residuals for all probes associated with a gene (metaprobeset) were obtained by performing a second round of RMA summarization (using APT) for all probesets associated with AltAnalyze core probeset, "extended" probeset, or "full" probeset definitions. FIRMA scores for each probeset and sample were further summarized by AltAnalyze along user-defined biological groups and comparisons to obtain a FIRMA fold change and P-value (two-tailed t-test assuming unequal variance). We used the 0.05 as P-value threshold. CORE probesets were used to perform general alternative splicing analysis, but "extended" and "full" probesets were used to visualize the global missplicing patterns using a heatmap. Specifically, probe sets with the core annotation include all Affymetrix core probe sets that specifically overlap with a single ENSEMBL gene, along with any probe set that overlaps with an ENSEMBL or UCSC exon. For exon/intron splicing assay of WT and *Vav*-TRAF6 LSK cells, the parameters for AltAnalyze program were as follows: dabg (P \< 0.05); raw expression threshold (1.0); alt exon fold variable (2.0); gene expression cutoff (3.0); P \< 0.05. For FIRMA, the median of the residuals for each probe set for each array sample is compared to the median absolute deviation for all residuals and samples for the gene, as previously described^[@R19],[@R44]^. To study splicing patterns of LPS-treated and untreated THP-1 cells, Gene Expression Omnibus dataset (GSE32141; Affymetrix HuEx1.0 ST exon array) was analyzed with the following parameters in AltAnalyze: dabg (P \< 0.05); raw expression threshold (1.0), alt exon fold variable (2.0); gene_expression cutoff (3.0); P \< 0.05. Details on the Splicing Index analysis are previously described^[@R18]^.

Splicing pattern enrichment analysis {#S17}
------------------------------------

Identification of alternative exons for 46 previously published splicing factor knockdown, over-expression or mutation datasets (mouse or human) was obtained using AltAnalyze, followed by over-representation analysis in GO-Elite ([Supplemental Table 5](#SD2){ref-type="supplementary-material"}). Enrichment Z scores for alternative exons from *Vav*-TRAF6 LSK among regulated exons from 46 evaluated splicing factors (siRNA, knock-out, over-expression, mutation). Only results for splicing factors with at least 4 matching regulated exons in comparison to TRAF6-overexpression patterns are shown. Enrichment was performed using GO-Elite separately for upregulated (increased exon-inclusion) and downregulated (increased exon-exclusion) separately for the input exons and evaluated splicing factor regulated exons. Splicing-factors with at least 10 exons regulated in common with the indicated splicing factor are shown. The splicing factor predicted expression (up or down-regulated) is indicated based on expression of the enriched exons in *Vav*-TRAF6 LSK.

RNA binding protein site enrichment analysis {#S18}
--------------------------------------------

Exon and intron sequences were retrieved using R/Bioconductor's (<http://www.bioconductor.org>) BSgenome packages. All exons and flanking introns (with explicit start-end coordinates) defined in TXdb (for SpliceTrap) and EnsMart65 (for AltAnalyze) were used as search spaces to compute the total occurrence and location of each predicted binding site (see below). Entire exon blocks (merged Ensembl transcript models from AltAnalyze) were scanned, along with 5' and 3' intron region sequences (50nt, 500nt and full intron windows from adjacent splice sites). Exon-inclusion, exon-exclusion and combined differentially regulated probe sets (FIRMA) were scanned separately. Only the exons passing basal expression filters and having explicit start-end coordinates were considered for further analysis (219219 for human RNA-seq data, 261178 for mouse exon array data). To examine these exon and intron sequences for putative binding sites for specific RNA binding proteins (RBPs), we used a public library of 228 human RBP binding models in the form of position frequency matrix motifs obtained from the CisBP-RNA database^[@R20]^, and supplemented them with 12 additional motifs for hnRNP family members. This collection of binding models was used to create a custom motif library in the HOMER software package^[@R45]^. We then used the HOMER algorithm to systematically estimate the significance of the presence of matches to each motif in each input sequence set, scanning only the sense strand in the RNA sequences.

As a complementary approach, we employed a consensus-based binding site enrichment analysis, wherein regular expression pattern searches were determined for a given consensus site on skipped and non-skipped exon sequences. For hnRNPA1 binding motif enrichment analysis, human and mouse consensus binding sites (AGNUAGNN, GUAGUAGU, UAGGGA, UAGGGU)^[@R24]--[@R26]^ were utilized. For exons containing binding site matches at multiple locations for a given consensus site, we counted multiple occurrences as "1" for our enrichment tests. Target exons were categorized into 4 groups: with binding site skipped; without binding site skipped; with binding site included; and without binding site included. Binding site enrichment was then performed using the hypergeometric test^[@R46]^.

For human AML, 179 patient (Level3) sample data sets were downloaded from TCGA website. 13 samples with high and 9 samples with low level of TRAF6 (in RPKM) were selected for splicing assay. Corresponding TCGA level-1 data (RNA-seq BAM files) were obtained through dbGaP ([ttps://dbgap.ncbi.nlm.nih.gov](http://ttps://dbgap.ncbi.nlm.nih.gov)) and CGHub UCSC (<https://cghub.ucsc.edu/datasets/data_sets.html>). Each BAM file was converted into two FASTQ files using PICARD's SamToFastq tool (v1.98) and used as inputs to SpliceTrap^[@R47]^. To quantify exon inclusion ratios based on paired-end reads using SpliceTrap (v0.90.5), each exon was analyzed with respect to adjacent exons flanking the middle spliced exons. The unpaired T-test was used in order to assess the difference of exon usage between these two groups. The exon inclusion ratio was defined as the expression level of the inclusion isoform divided by the total expression level of both isoforms (inclusion and skipped) derived from an exon trio. Inclusion ratio is used to separate constitutive exons (CS, inclusion ratio \> 0.9) and cassette/alternative exons (CA, inclusion ratio \< 0.9). Since SpliceTrap does not provide per-group analysis, we made arbitrary cutoff (\>75% in each group) for exons of interest showing the consistent alternative splicing patterns. As above, hnRNPA1 motif enrichment was determined by the hypergeometric test.

TRAF6 ubiquitin substrate identification by subtractive proteomics {#S19}
------------------------------------------------------------------

Identification of ubiquitinated peptides was performed in accordance to the manufacturer recommendations (PTMScan Ubiquitin Proteomics System, Cell Signaling Technology). TF1 cells transduced with a doxycycline-inducible TRAF6 shRNA were grown in RPMI1640 supplemented with FBS. Cells were treated with or without doxycycline for 24 hours. After treatment, cells were lysed in denaturing lysis buffer. Lysates were digested with trypsin followed by peptide desalting. Peptides were immunoprecipitated with αnti-diGly coupled to protein A agarose beads for 1 hour at 4°C. Eluted peptides were analyzed by LC-MS/MS on an ABSciex 5600 TripleTOF mass spectrometer coupled to an Eksigent nanoLC.ultra nanoflow HPLC system as described^[@R48]^. MS/MS spectra searches of the nano-LC-MS/MS data (\*.wiff file) from the enriched diGly peptides were processed for protein identification using ProteinPilot™ software (version 4.2, revision 1297) supplied by ABSciex. The data were searched against a SwissProt database of *Homo sapiens* protein sequences with "Biological Modifications" (which included diGly) as a specified defaults in the ProteinPilot software. The resulting \*.group file was then used to generate a spreadsheet as a peptide summary report. Peptides identified with a minimum of 99% confidence are reported. Data obtained from TRAF6-expressing (without doxycycline) and in TRAF6-depleted (with doxycycline) TF1 cells was used to generate a non-redundant list of diGly sites.

In vitro ubiquitination assay {#S20}
-----------------------------

Validation of hnRNPA1, TAK1, and Tubulin ubiquitination was performed in accordance with the manufacturer recommendations (E3 Substrate ID, LifeSensors, Inc). In vitro ubiquitin reconstitution assays were performed on two protein arrays (Invitrogen ProtoArray). Recombinant E1 (UBE1), E2 (UBE2N/UBE2V1), wild-type ubiquitin, and ATP were included in each reaction. One array also received a mix containing purified human TRAF6 protein. Arrays were visualized with Tandem Ubiquitin Binding Entities (TUBEs) and FK2 followed by the corresponding Cy-dye labeled secondary detection reagents. To calculate ubiquitination of hnRNPA1, TAK1, and Tubulin, median intensities subtracted from background intensities were utilized from biological replicates (F532 Median - B532 Median = ubiquitin intensity).

RNA immunoprecipitation {#S21}
-----------------------

RNA immunoprecipitation was performed as previously described^[@R49]^. Briefly, HEK 293 cells were crosslinked with 1% formaldehyde. Crosslinking was stopped by the addition of 200mM glycine. 500ug protein lysate was precleared with protein G Dynabeads (Life Technologies, 10007D), and immunoprecipitation was performed with 10ug of Myc antibody (Santa Cruz, sc-40) with rabbit IgG1 (Cell Signaling, 54153; negative control). RNA bound to the immunoprecipitated proteins was recovered by the treatment with proteinase K and DNase, and then measured with qRT-PCR. Primers to measure pre-mRNA are 5'-ATCTGAGAGAGTGGCTTTTTGC-3' and 5'-CTGCTTCTGGTGCCTTCTG-3'.

Patient samples {#S22}
---------------

Informed consent was obtained according to protocols approved by the review boards of MD Anderson Cancer Center and Cleveland Clinic. Diagnoses were reviewed and adapted, when required, to WHO 2008 criteria. For qRT-PCR analysis of *TRAF6* transcript and *ARHGAP17* missplicing, BM aspirates were collected from 36 MDS/AML patients and 7 age-matched healthy controls ([Supplemental Table 6](#SD2){ref-type="supplementary-material"}). RT-PCR analysis of *ARHGAP17* splicing was performed on TRAF6^high^ and TRAF6^low^ MDS/AML patients (as determined by qRT-PCR and selected for \> 2-fold or \< 1-fold TRAF6 mRNA expression) and healthy controls.

Cell lines and CD34^+^ cells {#S23}
----------------------------

TF1 and HEK293 cells were purchased from the American Type Culture Collection. MDSL was provided by Dr. Kaoru Tohyama (Kawasaki Medical School, Okayama, Japan). TF1 and MDSL cells were cultured in RPMI 1640 medium plus 10% FBS and 10ng/mL human recombinant interleukin 3 (rhIL-3, 02603, StemCell Technologies). HEK293 cells were maintained in DMEM media with 10% FBS. Human CD34^+^ cord blood cells were prestimulated in StemSpan SFEM supplemented with recombinant human stem cell factor (rhSCF; 02830 Stemcell Technologies), recombinant human Flt3 ligand (rhFL; 02840, Stemcell Technologies), recombinant human thrombopoietin (rhTPO; 02522, PeproTech) at 100ng/mL for 48 hours before transduction, and then maintained in rhSCF, rhFL, rhTPO, rhIL-3, and recombinant human IL-6 (rh IL-6; 02606 Stemcell Technologies) at 10ng/mL.

Colony forming assay {#S24}
--------------------

Murine LSK or BM mononuclear cells (MNC) were harvested from WT (FVB/NJ) and *Vav*-TRAF6 mice (FVB/NJ) (\~4 months of age), and plated in methylcellulose (3434; Stemcell Technologies). Colonies were counted at 12--14 days after plating. For knockdown of mouse hnRNPA1, Lin^−^ BM cells from WT (FVB/NJ) and *Vav*-TRAF6 mice were transduced with shRNA-expressing lentivirus, sorted for GFP^+^ cells by FACS, and plated in methylcellulose (3434; Stemcell Technologies). In addition, Lin^−^ BM cells from WT (C57Bl/6) mice were transduced with retrovirus encoding TRAF6 or ligase inactive TRAF6^C70A^, and sorted for GFP^+^ cells by FACS, and plated in methylcellulose (3434; Stemcell Technologies). For knockdown of human *ARHGAP17*, CD34^+^ cells were transduced with shRNA-expressing lentivirus, sorted for GFP^+^ cells by FACS, and plated in methylcellulose (4434, Stemcell Technologies).

Flow cytometry {#S25}
--------------

BM MNC were washed and incubated for 30 minutes with biotin conjugated lineage markers (CD11b, Gr1, Ter119, CD3, B220, Mouse Hematopoietic Lineage Biotin Panel, 88-7774-75, eBioscience), followed by staining with streptavidin APC-Cy™7 (554.63, BD Pharmingen), Sca-1 PE-cy7 (25-5981-82, eBioscience), c-Kit APC (17-1171-81, eBiosciences), CD34 FITC (11-0341-81, eBiosciences), CD135 (12-1351-81, eBiosciences). Long-term HSCs (LT-HSCs) were purified based on surface markers as Lin^−^Sca^−^1^+^c-Kit^+^CD34^−^CD135^−^. For colony forming assay using LSK cells, murine BM MNC were washed and incubated for 30 minutes with biotin conjugated lineage markers (CD11b, Gr1, Ter119, CD3, B220, Mouse Hematopoietic Lineage Biotin Panel, 88-7774-75, eBioscience), followed by staining streptavidin eFluor® 450 (48-4317-82, eBioscience), Sca-1 PE (12-5981-82, eBioscience), c-Kit APC (17-1171-81, eBiosciences). LSK cells were enriched based on surface markers as Lin^−^Sca^−^1^+^c-Kit^+^.

For immunophenotypic analysis of HSPC, murine BM were washed and incubated for 30 minutes with biotin conjugated lineage markers (CD11b, Gr1, Ter119, CD3, B220, Mouse Hematopoietic Lineage Biotin Panel, 88-7774-75, eBioscience), followed by staining with streptavidin eFluor® 450 (48-4317-82, eBioscience), Sca-1 PE-cy7 (25-5981-82, eBioscience), c-Kit APC-eFluor® 780 (47-1170-80, eBioscience), CD34 PE (551387, BD Biosciences), CD135 APC (17-1351-80, eBioscience), CD16/32 APC (17-0161-81, eBioscience). Short-term HSCs (ST-HSCs) were identified based on surface markers as Lin^−^Sca^−^1^+^c-Kit^+^CD34^+^CD135^−^, multipotential progenitors (MPPs) were with Lin^−^Sca^−^1^+^c-Kit^+^CD34^+^CD135^+^, common myeloid progenitor cells (CMP) were with Lin^−^Sca^−^1^−^c-Kit^+^CD34^+^CD16/32^−^, megakaryocyte-erythroid progenitor cells (MEP) were with Lin^−^Sca^−^1^−^c-Kit^+^CD34^−^CD16/32^−^, granulocyte-macrophage progenitor cells (GMP) were with Lin^−^Sca^−^1^−^c-Kit^+^CD34^+^CD16/32^+^. To study myeloid and lymphoid lineages, PB samples were treated with 1xRBC lysis buffer, washed and incubated with CD11b PE-cy5 (15-0112-82, eBioscience), Gr1 eFluor-450 (48-5931-82, eBioscience), CD3 PE (12-0031-83, eBioscience), B220 APC (17-0452-82, eBioscience). Otherwise, BM cells and splenocytes were stained with CD11b PE-cy5, Gr1 eFluor-450, CD3 PE, B220 APC, Ter119 PE-cy7 (25-5921-81, eBiosciences). Myeloid cells, including granulocytes and monocytes, were based on CD11b^+^ (Gr1^+^ or Gr1^−^), B lymphocytes were with B220^+^, T lymphocytes were with CD3^+^, erythroblasts were with Ter119^+^. After BMT and competitive transplantation, PB were stained with CD45.1 PE-cy7 (25-0453-82, eBioscience), CD45.2 APC-eFluor® 780 (47-0454-82, eBioscience), CD11b PE-cy5, CD3 PE, B220 APC, while BM were with lineage markers plus streptavidin eFluor® 450, CD45.1 PE-cy7, CD45.2 FITC (561874, BD Biosciences), Sca-1 PE (12-5981-81, eBioscience), c-Kit APC-eFluor® 780, CD135 PE-Cy5 (15-1351-81, eBiosciences), CD16/32 PerCP-Cy5.5 (45-0161-80, eBioscience), CD34 eFluor® 660 (50-0341-82, eBioscience) for lineage distribution and chimerism study. Analysis was performed using FACSCanto and/or LSRII flow cytometers with either Diva or FlowJo software.

Reagents and related assays {#S26}
---------------------------

Lin^−^ BM cells were exposed to 10 ng/mL LPS (TLRL-PEKLPS, InvivoGen) RNA was extracted to study exon skipping.

RT-PCR and qRT-PCR {#S27}
------------------

Total RNA was extracted and purified using Quick-RNA MiniPrep (Zymo research, R1055) and reverse transcription was carried out using SuperScript VILO cDNA Synthesis Kit (Invitrogen). PCR was performed with the following primers: *Arhgap1* forward 5'-CAGAGCTGCAAGATGACCTG-3' and reverse 5'-AAGAGCTTGCTGTGGTCCAG-3'; *Sema4g* forward 5'-CCTCCAGTTTCCTCTGTCCA-3' and reverse 5'-CTTGCTCCCATTGAGTAGCC-3'; *Mllt1* forward: 5'-CCCGACAGACAATGAGAGC-3' and reverse 5'-ATAGCCCGACTCCTCCACTT-3'; *Cep164* forward 5'-CAACGAGGAGGATGAAGAGG-3' and reverse 5'-CTCTTCCTTGGGACTTGCTG-3'. *Mtmr14* forward 5'-AGTCACTCATCCTCCCCACA-3' and reverse 5'-TGCTGTATGCAGCCAAGAAG-3'; *Slmap* forward 5'-ACAAGAGCTCCAGGCAAAAA-3' and reverse 5'-ATCCATCTGGGCGTCTGTAG-3'; *ARHGAP17* forward on exon 16 5'-CTCACCACCCCGAGTTCTAA-3', on exon 17 5'-GAGCTCTAGGGCTGAAAGCA-3', reverse on exon 19 5'-GACTGGGTGGATGCTGAGAT-3'. Densitometry was determined with Image J. Quantitative PCR was performed with Taqman Master Mix (Life Technologies) for human TRAF6 (Cat\# 4331182, Assay\# Hs00371512_g1), human hnRNPA1 (Cat\# 4453320, Assay\# Hs01656228_g1), mouse hnRNPA1 (Cat\# 4448892, Assay\# Mm02528230_g1), human GAPDH (Cat\# 4331182, Assay\# Hs02758991_g1), mouse GAPDH (Cat\# 4453320, Assay\# Mm99999915_g1) on an Applied Biosystems StepOne Plus Real-Time PCR System. All the probes were purchased from Applied Biosystems. To measure total *TRAF6* transcript level in *Vav*-TRAF6 LSK, primers were designed to amply both endogenous (mouse) and ectopic (human) *TRAF6*, with forward 5'-CTCAGCGCTGTGCAAACTATATATCCC-3' and reverse 5'-GGCGTATTGTACCCTGGAAGGG-3'. Mouse GAPDH was used as an internal control with forward primer 5'-ACTCAAGATTGTCAGCAATGCATCCTGC-3' and reverse primer 5'-ATGAGCCCTTCCACAATGCCAAAGTTG-3'. To quantitatively measure exon skipping, misspliced genes were selected with a smaller exon (\< 200bp) and ones that were less likely to undergo non-sense mediated decay. Primers were designed as follows: Cep164 forward 5'-GACAACCAGGAGTCTCCAAG-3' and reverse 5'- TTGAAGAAGCCTTGGGATCA-3'; *ARHGAP17* forward for exon 17 and exon 19 boundary 5'-CAGGCGACGGCAGCTGTTAAAAAAC-3', and reverse 5'-GACTGGGTGGATGCTGAGAT-3'; Mouse GAPDH and human β-actin were used as internal controls for murine and human samples, respectively. Primers for β-actin are forward 5'-CTCTTCCAGCCTTCCTTCCT-3' and reverse 5'-AGCACTGTGTTGGCGTACAG-3'.

Plasmids {#S28}
--------

Mouse Arhgap1 exon2 together with its 61 bp upstream and 52 bp downstream intronic sequence were amplified and inserted into pFlare minigene plasmids^[@R31]^. The control pFlare minigene plasmid containing a modified human β-globin gene cassette has been previously described^[@R31]^. Myc-tagged full-length human hnRNPA1 was synthesized and subcloned into pcDNA3.1. hnRNA1 mutant K3R and RRM K-R were generated with Quick Change Multisite-directed Mutagenesis Kit (200515, Agilent Technologies). FLAG-tagged TRAF6 vectors have been described previously^[@R50]^. Mouse *Arhgap1* 5-UTR fusions were synthesized by Blue Heron Biotech and cloned into pCMV6-A-GFP.

Transfection {#S29}
------------

Transfection was performed with HEK293 cells with TransIT^®^-LT1 Transfection Reagent (MIR2305, Mirus) according to the manufactures' recommendation.

Immunoblotting and immunoprecipiation {#S30}
-------------------------------------

Cells were lysed in cold RIPA buffer in the presence of PMSF, sodium orthovanadate, protease and phosphatase inhibitors. Protein concentration was evaluated by a BCA assay (32106, Pierce). For cytosol and nuclei protein fractionation, cytosol proteins were recovered in 10 mM Hepes pH 7.9, 10 mM KCl, 0,1 mM EDTA, 0,1 mM EGTA, 0,4 % NP40, 1 mM DTT, 0,1 mM PMSF, 10 µg/ml aprotonin, 1 mM OVA. For immunoprecipitation, TRAF6, hnRNPA1 or M2 antibodies (2µg) were added to cell lysates (1--5 mg) for 3 h at 4°C and captured by the addition of Protein A/G Plus beads (sc-2003; Santa Cruz) as described before^[@R51]^. The immune complexes were recovered and detected by immunoblotting. Western blot analysis was performed with the following antibodies: TRAF6 (sc-7221; Santa Cruz)^[@R52]^, ubiquitin (sc-8017; Santa Cruz), Myc-tag (2278; Cell Signaling), M2 (F3105; Sigma), Arhgap1/Cdc42gap (discontinued; BD Laboratories)^[@R29],[@R53]^, Cdc42 (ab64533; Abcam), hnRNPA1 (sc-10030; Santa Cruz), Tubulin (ab6160; Abcam), β-actin (4968; Cell Signaling), GAPDH (5174; Cell Signaling).

Cdc42-GTP pulldown assay {#S31}
------------------------

Cells were lysed with 20mM Tris/HCl pH 7.6, 100mM NaCl, 10mM MgCl, 1% Triton X-100, 0.2% SDS with protease and phosphatase inhibitors, incubated with glutathione-agarose beads coated with GST-PAK1 and processed further as described previously^[@R28]^.

Lentivirus production {#S32}
---------------------

Lentiviral shRNA expression vector (pLKO.1, OpenBiosystems) were obtained from the Lentiviral core at CCHMC and used to express shCTL (empty or scrambled control) and shRNA for human hnRNPA1 (TRCN0000006583, TRCN0000006586), mouse hnRNPA1 (TRCN0000055265) and human TRAF6 (TRCN0000007348), human *ARHGAP17* (TRCN0000047451). For knockdown of hnRNPA1, the majority of experiments were performed with clone TRCN0000006583. Lentivirus was generated as previously described^[@R52]^. An inducible knockdown of human TRAF6 was performed in pTRIPZ system (RHS4696-101315918; OpenBiosystems). After transduction of pTRIPZ, 3µg of puromycin was used for selection. Doxycycline was used to induce knockdown of TRAF6.

Statistical analysis {#S33}
--------------------

Unless otherwise specified, results are depicted as the mean ± standard error of the mean. Statistical analyses were performed using Student's t-test. For Kaplan-Meier analysis, Mantel-Cox test was used. GraphPad Prism (v5, GraphPad) was used for statistical analysis. For correlative analyses, Spearman rank test was used.

Data availability {#S34}
-----------------

The data that support the findings of this study are available from the corresponding author upon request.
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![Overexpression of TRAF6 results in hematopoietic stem/progenitor cell defects\
**(a)** TRAF6 mRNA in CD34^+^ BM cells from low-risk MDS patients (n = 36) and age-matched healthy controls (HC; n = 7) (left), and LSK cells from *Vav*-TRAF6 (n = 6) and WT FVB/NJ (n = 4) mice (primers are designed to measure both endogenous mouse *Traf6* and ectopic human TRAF6). P = 0.02. (**b**) Disease-free survival of *Vav*-TRAF6 (n = 60) and WT FVB/NJ mice (n = 40) \*, P = 0.009. (**c**) Complete blood counts for WT FVB/NJ (n = 33) and moribund *Vav*-TRAF6 (n = 18) mice. \*. P \< 0.01. (**d**) BM neutrophil dysplasia in age-matched WT (n = 3) and *Vav*-TRAF6 (n = 5) FVB/NJ mice. At least 100 cells were examined for each mouse. \*, P = 0.04. (**e**) BM mononuclear cell counts from WT (n = 3) and *Vav*-TRAF6 FVB/NJ mice (n = 4). \*, P = 0.004. (**f**) Representative Wright-Giemsa-stained peripheral blood smears (PB) and bone marrow cytospins (BM) from WT (FVB/NJ) and 2 moribund *Vav*-TRAF6 mice. The red arrow indicates dysplastic myeloid cells with Pseudo-Pelger Hüet anomaly. Scale bars, 10 µm (top) and 7.5 µm (bottom) (**g**) Number of long-term hematopoietic stem cells (LT-HSC, P = 0.0056), short-term HSC (ST-HSC, P = 0.0011), multipotent progenitors (MPP, P = 0.014), common myeloid progenitors (CMP), megakaryocyte-erythroid progenitor (MEP), and granulocyte-monocytic progenitor (GMP) in the BM of WT (C57Bl/6) (n = 4) and *Vav*-TRAF6 (n = 4) \~6 month old mice. (**h**) Colony numbers were determined after primary and secondary plating LSK BM cells from WT (FVB/NJ; n = 3) and *Vav*-TRAF6 (n = 3) mice in methylcellulose. \*, P \< 0.001. (**i**) FACS analysis of WT (C57Bl/6) or *Vav*-TRAF6 donor-derived (CD45.2^+^) and competitor-derived (CD45.1^+^) mononuclear cells from peripheral blood 12 weeks post competitive transplantation (left panel). Proportion of myeloid (CD11b^+^) and lymphoid (CD3^+^ and B220^+^) cells within the donor-derived compartment (gated on CD45.2^+^) after competitive transplantation with either BM mononuclear cells (MNC, left) or LT-HSC (right). (n = 8 mice per genotype) (right panel). \*, P \< 0.05. (**j**) Colony formation in methylcellulose after serial replating of GFP-sorted Lin^−^ BM cells (C57Bl/6) transduced with retroviral vectors (MSCV-IRES-GFP) encoding WT (n = 3) or an E3 ligase-mutant TRAF6 (TRAF6^C70A^, n = 3). \*, P \< 0.01. (**k**) Proportion of donor-derived (gated on CD45.2^+^;GFP^+^) peripheral blood myeloid (Cd11b^+^) and lymphoid (CD3^+^ and B220^+^) cells were examined by FACS for competitively transplanted GFP-sorted Lin^−^ BM cells (C57Bl/6) transduced with retroviral vectors encoding WT (n = 5) or an E3 ligase-mutant TRAF6 (TRAF6^C70A^, n = 10) co-expressing GFP (MSCV-IRES-GFP). \*, P \< 0.05. Data are from three experiments (**a, c--g**; means and s.e.m.) or from two experiments (**h--k**; means and s.e.m.).](nihms833529f1){#F1}

![TRAF6 regulates ubiquitination of RNA binding proteins and RNA splicing\
(**a**) In vitro Ub reconstitution assays were performed on the identified candidates from the cell-based screen with purified TRAF6 (n = 29). Shown is the substrate ubiquitination in the presence of TRAF6 (F532 CyDye) as compared to without TRAF6 (B532 CyDye) for 2 independent replicates. (**b**) Exon-level microarray expression analysis of LSK from 6 month WT (FVB/NJ, n = 4) and *Vav*-TRAF6 mice (n = 3). (**c**) Motif enrichment in differentially spliced exons from *Vav*-TRAF6 LSK as compared to WT LSK in the form of position frequency matrix motifs from the CisBP-RNA database. Each point represents one motif. Motifs are sorted left to right in decreasing order of significance. Motifs enriched in *Vav*-TRAF6 LSK are above the horizontal dotted line. hnRNPA1, P = 9.7x10^−5^. (**d**) Enrichment scores for exon usage patterns for *Vav*-TRAF6 LSK as compared to 46 known splicing factor exon usage patterns. Each point represents the enrichment Z-score for an individual splicing pattern of the splicing factor patterns examined. Exon usage patterns enriched in *Vav*-TRAF6 LSK are above the horizontal dotted line. hnRNPA1, P = 0.017. Data are from two experiments (**a**; means and s.d.).](nihms833529f2){#F2}

![TRAF6 ubiquitinates hnRNPA1\
(**a**) In vitro ubiquitin reconstitution assay performed in duplicate and analyzed by CyeDye fluorescence (F532 subtracted from background, B532) for hnRNPA1, TAK1, and Tubulin (TUBB; a negative control). Individual assays contained recombinant Ub, UBE1, Ubc13/UBE2V1, ATP, and the indicated substrates. nd, not detectable. (**b**) HEK293 cells transfected with MYC-hnRNPA1, FLAG-TRAF6, and either WT HA-Ub or mutant Ub that form only K63- (Ub^K63^) or K48- (Ub^K48^) linkages were immunoblotted for HA (Ub) on IP MYC-hnRNPA1. (**c**) HEK293 cells transfected with MYC-hnRNPA1, and either WT or E3 ligase defective (C70A) TRAF6 were IB for IP MYC-hnRNPA1 (anti HA-Ub). (**d**) Schematic representation of hnRNPA1 protein, and corresponding lysine-to-arginine mutations within the RNA recognition motif (RRM) (above image). HEK293 cells transfected with WT, Lys3-mutant hnRNPA1 (K3R), or hnRNPA1 with mutation of the lysines within the first RRM domain (K--R) were immunoprecipitated (IP) for MYC-hnRNPA1 and then immunoblotted for HA (Ub). Data are from two experiments (**a**; means and s.d.).](nihms833529f3){#F3}

![hnRNPA1 contributes to the hematopoietic phenotype in *Vav* TRAF6 mice\
(**a**) Immunoprecipitation and immunobloting of ubiquitinated hnRNPA1 from WT (FVB/NJ) and *Vav*-TRAF6 Lin^−^ BM cells and LPS-treated WT (C57Bl/6) (*Traf6*^+/+^) and TRAF6-deficient (*Traf6*^−/−^) Lin^−^ BM cells. (**b**) hnRNPA1 mRNA and protein expression was determined following expression of shRNAs targeting hnRNPA1 (shA1) or non-targeting shRNA (shCtl). (**c**) Colony formation in methylcellulose after serial replating of GFP-sorted WT (FVB/NJ, n = 3) and *Vav*-TRAF6 (n = 3) Lin^−^ BM cells transduced with shRNAs targeting hnRNPA1 (shA1) or control shRNA (shCtl) co-expressing GFP. \*, P \< 0.05; ^\#^, P = 0.08. (**d**) Chimerism of donor-derived (CD45.2^+^GFP^+^) peripheral blood cells from lethally-irradiated recipient mice receiving Lin^−^ BM cells transduced with shRNAs targeting hnRNPA1 (shA1) or control shRNA (shCtl) co-expressing GFP competitively transplanted with wild-type (CD45.1^+^) total BM cells (n = 8 per genotype). \*, P \< 0.05. Data are from two experiments (**b--d**; means and s.e.m.).](nihms833529f4){#F4}

![TRAF6 regulates RNA splicing of Arhgap1\
(**a**) Significantly excluded or included exons as determined by FIRMA index (−4.0 ≥ *a* ≤ 4.0) in *Vav*-TRAF6 versus WT (FVB/NJ) LSK (MIDAS P \< 0.05). Each point represents a differentially spliced exon. Highlighted are the top 3 differentially spliced exons in *Vav*-TRAF6 LSK. (**b**) Schematic representation of the mouse *Arhgap1* gene structure with the approximate position of exons and introns. Overview of *Arhgap1* exon usage is shown for WT (FVB/NJ) (black lines) and *Vav*-TRAF6 LSK (red lines). The average of FIRMA index values for individual exons of *Arhgap1* in WT (n = 4) and *Vav*-TRAF6 LSK (n = 3) are shown below. FIRMA index scores indicate exon exclusion (negative values) or exon retention (\~0). (**c**) RT-PCR analysis (using primers flanking exon 2) of the *Arhgap1* cassette exon in *Vav*-TRAF6 and WT (FVB/NJ) LSK (left), and in LPS-treated WT Lin^−^ BM cells (right). Values under the plot represent the short isoform as a percentage of the short and long isoforms. **(d)** Sequence analysis of the *Arhgap1* cassette exon using primers flanking skipped exon 2 isolated from *Vav*-TRAF6 LSK. (**e**) RT-PCR analysis (using primers flanking exon 2, as depicted in the schematic) of the *Arhgap1* cassette exon in WT (FVB/NJ) or *Vav*-TRAF6 Lin^−^ BM cells were transduced with non-targeting shRNA (shCtl) or shRNA targeting mouse hnRNPA1 (shA1). Summary of *Arhgap1* exon 2 exclusion calculated based on the short isoform as a percentage of the short and long isoforms is shown above. n = 3 per group; ^\#^, P = 0.06; \*, P = 0.04. (**f**) RT-PCR analysis (using primers flanking exon 2, as depicted in the schematic) of the *Arhgap1* cassette exon in WT (C57Bl/6) (*Traf6*^+/+^;Mx1Cre) and TRAF6-deficient Lin^−^ BM cells (*Traf6*^fl/fl^;Mx1Cre mice treated with PolyIC) stimulated with 10 ng/mL of LPS for 2 hrs. Summary of *Arhgap1* exon 2 exclusion calculated based on the short isoform as a percentage of the short and long isoforms is shown above. n = 3 per group; \*, P \< 0.05. (**g**) RT-PCR analysis of a minigene plasmid containing the *Arhgap1* cassette exon 2 with 50 bp of flanking intron sequences (using primers flanking exon 2, as depicted in the schematic on the left) in HEK293 cells (HEK293-*Arhgap1*exon2) transfected with hnRNPA1. Summary of *Arhgap1* exon 2 exclusion from the minigene calculated based on the short isoform as a percentage of the short and long isoforms is shown above from 2 independent experiments. \*, P = 0.02. (**h**) RT-PCR analysis of a minigene plasmid containing the *Arhgap1* cassette exon 2 (using primers flanking exon 2, as depicted in the schematic on the left) in HEK293-*Arhgap1*exon2 cells transfected with WT (n = 7) and an E3 ligase-mutant (C70A; n = 5) TRAF6. Summary of *Arhgap1* exon 2 exclusion from the minigene was calculated based on the short isoform as a percentage of the short and long isoforms is shown above from 2 independent experiments. \*, P = 0.03. (**i**) RT-PCR analysis of a minigene plasmid containing the *Arhgap1* cassette exon 2 (using primers flanking exon 2, as depicted in the schematic on the left) in HEK293-*Arhgap1*exon2 cells transfected with TRAF6 and hnRNPA1 (WT and lysine mutants). Summary of *Arhgap1* exon 2 exclusion from the minigene was calculated based on the short isoform as a percentage of the short and long isoforms is shown above from 2 independent experiments (n = 2 per group). Vec, vector; A1^WT^, hnRNPA1 WT; A1^K3R^, hnRNPA1 with K3R mutation; A1^K-R^, hnRNPA1 with mutation of all lysines within the first RNA recognition motif. \*, P \< 0.01; \*\*, P = 0.003. (**j**) qRT-PCR of *Arhgap1* cassette exon 2 expressed from the minigene plasmid following RNA immunoprecipitation of Myc-hnRNPA1 in HEK293-*Arhgap1*exon2 cells transfected with Myc-hnRNPA1 (WT and K-R) and TRAF6. Shown is the average of 2 independent experiments (n = 2 per group). \*, P \< 0.01. Data are from two experiments (**e--j**; means and s.e.m.).](nihms833529f5){#F5}

![Exclusion of exon 2 results in reduced Arhgap1 protein and Cdc42 activation\
(**a**) Schematic of the *Arhgap1* 5'-UTR and coding region. uORF, upstream open reading frame; HA, hemagglutinin. The indicated *Arhgap1* 5'-UTR cDNA fusions were transfected (pCMV-GFP) into HEK293 cells and evaluated by Arhgap1 and HA immunoblotting. Transfected *Arhgap1* 5'-UTR cDNA were measured by RT-PCR using primers aligned to Arhgap1 coding sequences. (**b**) Microarray and qRT-PCR analysis of *Arhgap1* total RNA from LSK of WT (FVB/NJ) and *Vav*-TRAF6 mice. (**c**) Immunoblotting of Arhgap1 in Lin^−^ BM cells from WT (FVB/NJ) and *Vav*-TRAF6 mice. Cdc42 activity (Cdc42-GTP) in WT (FVB/NJ) and *Vav*-TRAF6 Lin^−^ BM cells was determined by a pull-down/immunoblot assay. Shown is a representative blot from one WT (FVB/NJ) and three *Vav*-TRAF6 mice. (**d)** Densitometric analysis of Arhgap1 protein and Cdc42-GTP (WT, n = 3; *Vav*-TRAF6, n = 5). \*, P \< 0.05. Data are from three experiments (**b,d**; means and s.e.m.).](nihms833529f6){#F6}

![Cdc42 contributes to HSPC defects in *Vav* TRAF6 mice\
**(a)** FACS analysis of donor-derived (gated on CD45.2^+^) myeloid (CD11b^+^Gr1^+^) and lymphoid (B220^+^ and CD3^+^) proportions 8 weeks post transplantation for competitively transplanted WT (C57Bl/6) and *Vav*-TRAF6 LT-HSC, and for *Vav*-TRAF6 LT-HSC treated *in vitro* with CASIN (or DMSO) for 24 hr. \*, P \< 0.05. (**b**) Summary of independent experiments of myeloid and lymphoid proportions of donor-derived (gated on CD45.2^+^) peripheral blood shown as a ratio (CD11b/\[B220 + CD3\]). (**c**) Peripheral blood myeloid (CD11b^+^) and lymphoid (B220^+^ and CD3^+^) chimerism (CD45.2^+^) of donor-derived cells determined 8 weeks after competitive transplantation with *Vav*-TRAF6 LT-HSC treated with CASIN. (n = 6 per group). \*, P \< 0.005. **(d)** Donor-derived LT-HSC cells (CD45.2^+^) from *Vav*-TRAF6 mice and competitor BM cells (CD45.1^+^) were transplanted into lethally-irradiated recipient mice (CD45.1^+^). Three month post secondary transplantation, the recipients were treated with 30 mg/kg CASIN and vehicle control (PBS) for 16 days. Ratio of donor-derived (gated on CD45.2^+^) and competitor-derived (gated on CD45.1^+^) myeloid (CD11b) and lymphoid (CD3 and B220) cells was determined by flow cytometry 4 weeks post-CASIN treatment in vivo. Donor-derived chimerism is normalized (1.0) for each mouse at week 1 (n = 5 per group). \*, P = 0.007. Data are from two experiments (**b--d**; means and s.e.m.).](nihms833529f7){#F7}

![Cdc42 activation is associated with primary human MDS\
(**a**) RT-PCR using primers flanking endogenous *ARHGAP17* exon 18 or exons 17 and 18 (as depicted in the schematic on the left) in HEK293 or MDSL cells expressing shRNAs targeting TRAF6 (shTRAF6) or a non-targeting control (shCtl). (**b**) Immunoblotting of ARHGAP17 in independently transduced MDSL cells (MDSL-1-2) expressing a non-targeting shRNA (shCtl) or shRNA targeting TRAF6 (shTRAF6). (**c**) Sequence analysis of the *ARHGAP17* exons 16, 17, 18, and 19 in MDSL cells. (**d**) RT-PCR using primers flanking endogenous *ARHGAP17* exon 18 (as depicted in the schematic on the left) in MDS patient BM mononuclear cells with high (\>2-fold *TRAF6*, n = 3) or low (\< 1.0-fold *TRAF6*, n =3) TRAF6 mRNA, and 1 normal BM sample. (**e**) qRT-PCR of *ARHGAP17* exon 18 using primers to the exon 17--19 junction and normalized to total *ARHGAP17* in MDS/AML BM cells (n = 35). Spearman correlation: r = 0.3854, P = 0.014. (**f**) Cdc42-GTP pulldown assays in MDSL cells expressing non-targeting shRNA (shCtl) or shRNA targeting TRAF6 (shTRAF6), or in MDSL treated with 2.5 µM CASIN. (**g**) Cdc42-GTP pulldown assays in MDSL expressing non-targeting shRNA (shCtl) or shRNA targeting *ARHGAP17* (shGAP17). (**h**) Colony formation in methylcellulose of human CD34^+^ cells expressing a non-targeting shRNA (shCtl) or shRNA targeting *ARHGAP17* (shGAP17) (n = 3). \*, P = 0.047. Data are from three experiments (**h**; means and s.e.m.).](nihms833529f8){#F8}

[^1]: Present address: Department of Drug Discovery and Biomedical Sciences, South Carolina College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
